We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
BiondVax Pharmaceuticals Ltd | NASDAQ:BVXV | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.36 | 1.23 | 1.38 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of February, 2021
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
BiondVax Pharmaceuticals Ltd. (hereinafter, the “Company”) announces that it is scheduling an Extraordinary Meeting of Shareholders on March 31, 2021 at 4:00 p.m. Israel time at the offices of the Gross & Co., One Azrieli Center, Tel Aviv 6701101, Israel.
The Company hereby furnishes as Exhibit 99.1 to this Form 6-K a Notice with respect to the Company’s Extraordinary Meeting of Shareholders to be held on March 31, 2021.
Exhibit Index
Exhibit No. | Description | |
99.1 | Notice of Extraordinary Meeting of Shareholders |
Exhibit 99.1 is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Registration No. 333-240189) and its Registration Statement on Form S-8 (Registration No. 333-239344).
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BiondVax Pharmaceuticals Ltd. | ||
Date: February 17, 2021 | By: | /s/ Mark Germain |
Mark Germain | ||
Chairman of the Board |
2
1 Year BiondVax Pharmaceuticals Chart |
1 Month BiondVax Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions